Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers

Platelets

Volumn 24, Issue 8, 2013, Pages 615-624

  Teng, Renli ^a   Maya, Juan ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antiplatelet therapy; Aspirin; Clopidogrel; P2Y12 receptor antagonist; Pharmacokinetics; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; TICAGRELOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ADENOSINE DIPHOSPHATE; ADULT; ASPIRIN; BLEEDING TIME; COLLAGEN; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84885896667     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.748185     Document Type: Article

References (28)

1. Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y receptor antagonist. Cardiovasc Ther 2009;27:259-274.
2. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. for the PLATO investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
3. Brilinta TM, US full prescribing information, July 2011. [Accessed 18 July 2012] Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/ 2011/022433s000lbl.pdf
4. Brilique, summary of product characteristics, 2010. [Accessed 18 July 2012]. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR- Product-Information/human/001241/ WC500100494.pdf
5. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College fo Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:7S-47S.
6. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999-3054.
7. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-e122.
8. Teng R, Oliver S, Hayes M, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-1521.
9. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor: Areversibly binding oral P2Y12 receptor antagonist in healthy subjects. Eur J Clin Pharmacol 2010;66:487-496.
10. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852-1856.
11. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonise AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
12. Wu KK. Aspirin and other cyclooxygenase inhibitors: New therapeutic insights. Semin Vasc Med 2003;3:107-112.
13. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
14. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infraction, and stroke in high risk patients. Br Med J 2002;324:71-86.
15. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
16. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness and side effects. Chest 2001;119:39S-63S.
17. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 2007;297:2018-2024.
18. Berger JS, Sallum RH, Katona B, Maya J, Ranganathan G, Xu Y, Mwamburi M. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J 2012;164:153-162.e5.
19. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, et al. on behalf of the PLATO investigators. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011; 124:544-554.
20. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B. 2010; 878:2299-2306.
21. Butler K, Teng R. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70:65-77.
22. Srámek R, S rámek A, Koster T, Briet E, Rosendaal FR. A randomized and blinded comparison of three bleeding time techniques: The Ivy method, and the Simplate II- method in two directions. Thromb Haemost 1992;67:514-518.
23. Penz SM, Bernlochner I, To'th O, Lorenz R, Calatzis A, Siess W. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010;8:9.
24. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, Vaidya D. Platelet inhibition by 81 and 325 mg aspirin daily in men vs. women without clinically apparent cardiovascular disease. Am J Cardiol 2008;101:1359-1363.
25. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non- ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 Trial. J Am Coll Cardiol 2007; 50:1844-1851.
26. Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects. Can J Clin Pharmacol 2008;15:e426.
27. Armstrong PCJ, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9:552-561.
28. Kirkby NS, Leadbeater PDM, Chan MV, Nylander S, Mitchell JA, Warner TD. Anti-platelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haem 2011; 9:2103-2105.